Crossmark

Monthly tegafur–uracil maintenance for increasing relapse-free survival in ypStage III rectal cancer patients after preoperative radiotherapy, radical resection, and 12 postoperative chemotherapy cycles: a retrospective study

Crossref DOI link: https://doi.org/10.1186/s12885-019-6019-0

Published Online: 2019-08-17

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kuo, Yi-Hung

Lai, Chia-Hsuan

Huang, Cheng-Yi

Chen, Chih-Jung

Huang, Yun-Ching

Huang, Wen-Shih

Chin, Chih-Chien
License Information

Text and Data Mining valid from 2019-08-17

Version of Record valid from 2019-08-17
More Information

Article History

Received: 8 October 2018

Accepted: 6 August 2019

First Online: 17 August 2019

Ethics approval and consent to participate

: Before patient data collection, we applied for the appropriate ethics approval and obtained it from the Institutional Review Board (IRB) of Chang Gung Memorial Hospital (IRB No.: 201601450B0). Although all patients receiving chemotherapy are required to provide complete informed consent before undergoing adjuvant, neoadjuvant, or palliative chemotherapy in clinical practice, the IRB exempted us from the informed consent for patients’ participation because our study design was retrospective.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below